- Home
- MRSN vs MACI Comparison
MRSN vs MACI Comparison
Compare MRSN & MACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- MACI
- Stock Information
- Founded
- MRSN 2001
- MACI 2024
- Country
- MRSN United States
- MACI United States
- Employees
- MRSN N/A
- MACI N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- MACI
- Sector
- MRSN Health Care
- MACI
- Exchange
- MRSN Nasdaq
- MACI NYSE
- Market Cap
- MRSN 230.0M
- MACI 215.8M
- IPO Year
- MRSN 2017
- MACI 2024
- Fundamental
- Price
- MRSN $2.21
- MACI $10.05
- Analyst Decision
- MRSN Buy
- MACI
- Analyst Count
- MRSN 6
- MACI 0
- Target Price
- MRSN $6.00
- MACI N/A
- AVG Volume (30 Days)
- MRSN 1.1M
- MACI 24.5K
- Earning Date
- MRSN 11-13-2024
- MACI 01-01-0001
- Dividend Yield
- MRSN N/A
- MACI N/A
- EPS Growth
- MRSN N/A
- MACI N/A
- EPS
- MRSN N/A
- MACI N/A
- Revenue
- MRSN $34,837,000.00
- MACI N/A
- Revenue This Year
- MRSN N/A
- MACI N/A
- Revenue Next Year
- MRSN $7.15
- MACI N/A
- P/E Ratio
- MRSN N/A
- MACI N/A
- Revenue Growth
- MRSN N/A
- MACI N/A
- 52 Week Low
- MRSN $1.22
- MACI $9.95
- 52 Week High
- MRSN $6.28
- MACI $10.05
- Technical
- Relative Strength Index (RSI)
- MRSN 51.26
- MACI N/A
- Support Level
- MRSN $2.12
- MACI N/A
- Resistance Level
- MRSN $2.83
- MACI N/A
- Average True Range (ATR)
- MRSN 0.24
- MACI 0.00
- MACD
- MRSN 0.03
- MACI 0.00
- Stochastic Oscillator
- MRSN 39.81
- MACI 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.